Helix BioPharma Corp

Novel Antibody-Drug Conjugate L-DOS47 Shows Safety Profile in Phase I/II NSCLC Trial

- L-DOS47, a novel antibody-drug conjugate targeting CEACAM6-expressing tumors, demonstrated safety and tolerability in a Phase I/II trial of 76 non-small cell lung cancer patients at doses up to 13.55 μg/kg. - The drug's unique mechanism involves converting urea to ammonia and bicarbonate at the tumor surface to reverse acidosis in the tumor microenvironment, representing a first-in-class approach to combat tumor acidity. - While no complete or partial responses were observed in monotherapy, exploratory analyses showed median progression-free survival of 4.1 months in the highest dosing quartile, with 93% of these patients having received two or more prior therapies. - Post-hoc immunohistochemistry analysis revealed that 45.2% of NSCLC cases expressed high levels of CEACAM6, suggesting patient screening for this biomarker could improve treatment selection in future trials.